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Seminal studies showed that CRISPR-Cas systems provide adaptive immunity in prokaryotes
and promising gene-editing tools from bacteria to humans. Yet, reports diverged on whether
some CRISPR systems naturally target DNA or RNA. Here, Samai and colleagues unify the
studies, showing that a single type III CRISPR-Cas system cleaves both DNA and RNA targets,
independently.Just a decade ago, clustered regularly
interspaced short palindromic repeats
(CRISPR) and CRISPR-associated (Cas)
genes were poorly understood genomic
loci documented in almost all archaea
and many bacteria (van der Oost et al.,
2014). With no known function, the prev-
alence of these loci across highly
compact prokaryotic genomes remained
puzzling. Perhaps the only clue came
from the observation by three groups
that known CRISPR ‘‘spacer’’ sequences
often matched viral and plasmid se-
quences (Makarova et al., 2006). This
bioinformatic observation led to the hy-
pothesis that CRISPR-Cas loci may be
prokaryotic adaptive immune systems—
continually incorporating new spacer se-
quences from viral genomes and storing
these spacers to cleave complementary
viral RNAs in subsequent infections
through an antisense mechanism akin to
eukaryotic RNA interference (Makarova
et al., 2006). Remarkably, the adaptive
immunity hypothesis was validated in
viral challenge experiments a year later
(Barrangou et al., 2007) and was sub-
sequently later generalized to the two
other modes of genomic invasion in pro-
karyotes: conjugation and transformation
(Marraffini and Sontheimer, 2008; van der
Oost et al., 2014).
Yet, the emerging experimental picture
of CRISPR as an antisense adaptive
immune system differed from the early
bioinformatic predictions in one mecha-
nistic respect: spacers appeared to
target foreign DNA rather than RNA (Mar-
raffini and Sontheimer, 2008). The only
potential exceptions to DNA interference964 Cell 161, May 21, 2015 ª2015 Elsevier Inoccurred in a subset of CRISPR-Cas
systems known as type III systems,
where the field split on whether DNA (Ha-
toum-Aslan et al., 2014; Marraffini and
Sontheimer, 2008) or RNA (Hale et al.,
2009; Staals et al., 2014; Tamulaitis
et al., 2014) is targeted. A study in this
issue of Cell (Samai et al., 2015) now re-
solves this debate—elegantly showing
that a single type III system cleaves
both DNA and RNA, via independent
active sites (Figure 1).
Samai et al. (2015) build on a series
of seminal in vivo studies by Marraffini
and colleagues, which employed the
type III system encoded by a pathogenic
isolate (RP162A) of the bacterium Staphy-
lococcus epidermis. These earlier studies
showed that a type III locus can inhibit
plasmid establishment and the atten-
dant spread of antibiotic resistance, pro-
vided that a spacer sequence matches a
plasmid DNA sequence (Hatoum-Aslan
et al., 2014; Marraffini and Sontheimer,
2008). Yet, spacer identity with plasmid
RNA transcripts was shown to be insuffi-
cient for anti-plasmid immunity without
DNA identity. Taken together, the in vivo
data indicated that type III CRISPR sys-
tems confer immunity by targeting foreign
DNA; however, a direct demonstration of
DNA cleavage by a type III CRISPR sys-
tem had never been performed.
To directly assess whether a type III
CRISPR system cleaves complementary
DNA, Samai et al. (2015) purify the
Cas10-Csm effector complex, which
mediates immunity in S. epidermis
(Hatoum-Aslan et al., 2014). The ribonu-
cleoprotein complex consists of five pro-c.teins—Cas10, Csm2, Csm3, Csm4, and
Csm5—as well as a processed spacer
RNA that serves as a guide RNA.
Strikingly, the authors initially capture
no cleavage of DNA oligonucleotides
complementary to the spacer RNA.
Only when they induce transcription
of the DNA targets—using an oligonucle-
otide-based system that enables elonga-
tion via RNA polymerase (RNAP)—is DNA
cleavage seen. As a control, they also use
a small-molecule inhibitor to block RNAP
elongation. Consistent with transcription
dependence, inhibiting RNAP elongation
inhibits DNA cleavage.
In addition to providing a mechanism
for DNA interference in vivo, tran-
scription dependence may explain the
lack of DNA cleavage observed in
previous studies. In fact, the earlier
in vitro studies only demonstrated RNA
targeting and cleavage (Hale et al.,
2009; Staals et al., 2014; Tamulaitis
et al., 2014). Matching these studies,
when Samai et al. (2015) pit their purified
Cas10-Csm complex against comple-
mentary RNA sequences, they also
observe RNA cleavage. However, the
authors go further and decouple the
molecular drivers of DNA and RNA
cleavage, showing that DNA cleavage
requires an intact palm polymerase
domain in Cas10, while RNA cleavage
requires an independent active site in
Csm3. As a result, DNA cleavage can
be mutationally inactivated with no
impact on RNA cleavage, and vice versa.
By demonstrating that a single CRISPR
complex independently cleaves both
RNA and DNA, Samai and colleagues
Figure 1. Unified Model of DNA and RNA Cleavage by Type III CRISPR-Cas Systems
(A) The previously prevailing in vitro model in which type III CRISPR-Cas systems cleave RNA targets through an active site in the Csm3 protein (Hale et al., 2009;
Staals et al., 2014; Tamulaitis et al., 2014). Notably, both Csm3 and Cas10 (discussed below) reside in the larger Cas10-Csm complex, which is not shown for
simplicity.
(B) The competing model in which complementary DNA, rather than RNA, is targeted (Marraffini and Sontheimer, 2008). In vivo, CRISPR targeting of DNA had
been shown to require Cas10 (Hatoum-Aslan et al., 2014), yet in vitro demonstrations of DNA cleavage remained elusive.
(C) The unified model proposed by Samai et al. (2015), in which a single type III CRISPR-Cas system cleaves both complementary DNA (via Cas10) and RNA (via
Csm3). Notably, DNA cleavage is transcription dependent and only occurs on the non-template strand. The broad tropism for both DNA and RNA targets may
provide a critical evolutionary advantage.generalize (rather than contradict) the ex-
isting model of RNA-targeted immunity in
type III systems.
From an evolutionary standpoint, the
distinct RNA and DNA cleavage sites
imply that both RNA and DNA targeting
have been independently conserved
by natural selection. Yet, the in vivo
data of Samai et al. (2015) lead one
to question why RNA interference has
been preserved. When the authors
test RNA interference alone—by only
mutationally abrogating DNA interfer-
ence—they find that plasmid establish-
ment and cell death due to DNA phage
infection are only minimally reduced.
While a previous study did find that
RNA targeting provides robust immu-nity against an RNA phage in a single-
round viral challenge assay (Tamulaitis
et al., 2014), maintaining long-term immu-
nity against RNA phages in the wild with a
sequence-specific CRISPR system could
prove difficult. RNA phages have muta-
tion rates that are approximately three
logs higher than dsDNA phages, implying
that an anti-RNA CRISPR system would
need to acquire new spacers extremely
rapidly to stay apace (Weinberger et al.,
2012). And even if long-term immunity
against RNA phages could be maintained
in the wild (or in a chemostat), RNA
phages are estimated to represent just
1% of the total phage population.
Another possibility is that the conserved
RNA targetingpathwaymaybedirected atCellDNA phages and plasmids, rather than
RNA phages. RNA targeting could thus
provide a built-in redundancy to DNA tar-
geting—enabling a type III CRISPR sys-
tem to cleave mRNA transcripts in case it
misses the cognate DNA sequence. Sup-
porting this hypothesis, the data in Samai
et al. (2015) do show that mRNA cleavage
increases the probability of bacterial
survival during DNA phage infection,
although mRNA cleavage is orders of
magnitude less protective than DNA
cleavage. If this increase in bacterial
fitness accounts for the conservation of
RNA targeting in type III systems, it will
be interesting to see whether future
studies uncover similar RNA-targeting
mechanisms in type I or II systems.161, May 21, 2015 ª2015 Elsevier Inc. 965
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